EATG » Hepatitis

Hepatitis

Sofosbuvir-based therapy achieves excellent SVR12 rates among people who inject drugs in Ukraine

People who inject drugs (PWID) can have an excellent response to sofosbuvir-based therapy for hepatitis C virus (HCV) infection, Ukrainian research presented to the recent 2016 AASLD Liver Meeting shows.…

6 weeks of sofosbuvir/ledipasvir cures genotype 1 acute hepatitis C

A short course of sofosbuvir/ledipasvir (Harvoni) taken for 6 weeks cured 100% of HIV-negative people with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads,…

GS-4774 therapeutic vaccine shows little efficacy in people with hepatitis B

An experimental immune-based therapy for chronic hepatitis B combined with tenofovir was safe and well-tolerated, but did not lead to greater reductions in hepatitis B surface antigen (HBsAg) than the…

Arrowhead focuses resources on subcutaneous and extra-hepatic RNAi therapeutics

PASADENA, Calif., Nov 29, 2016 -- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a strategic redeployment of resources to support the development of RNAi therapeutics that utilize the company's new…

Phase 2b study of JNJ-4178 in chronic HCV initiated

NEW HAVEN, Conn., Nov. 30, 2016 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the start of patient dosing in a global Phase 2b open-label OMEGA-1 study of JNJ-4178, a 3DAA combination…

Hepatitis C virus infection is rising among gay and bisexual men in San Diego

The prevalence of hepatitis C virus (HCV) infection among HIV-positive men who have sex with men in San Diego has increased over the past 15 years, especially among men who…

Hepatitis C sheds enough in the rectum to transmit through anal sex

Researchers have come up with the first direct evidence that enough hepatitis C virus (HCV) sheds into the rectums of HIV-positive men who have sex with men (MSM) to transmit…

Mylan signs sub-license agreement with the Medicines Patent Pool for hepatitis C treatment

Mylan signs sub-license agreement with the Medicines Patent Pool to increase access to hepatitis C treatment in developing countries HERTFORDSHIRE, England and BENGALURU, India, Nov. 28, 2016 -- Mylan N.V.…

Non-adherence most important risk factor for sofosbuvir/ledipasvir failure

Research carried out by Mount Sinai Medical Center, New York, found that non-adherence was the strongest risk factor for treatment failure in people taking sofosbuvir/ledipasvir (Harvoni). The main reasons cited…

Portal hypertension less likely to fall after HCV treatment when liver stiffness is severe

Curing hepatitis C infection moderately reduces portal hypertension, but has less impact in people with more severe liver stiffness due to fibrosis, Spanish researchers reported at the 2016 AASLD Liver…